Ind Swift Laboratories Quarterly Results for Trading Insights
In Sept 2025, Ind Swift Laboratories (INDSWFTLAB) reported revenue ₹171 Cr and net profit ₹8 Cr — revenue +584.0% YoY. For annual financials, live price and key ratios, visit INDSWFTLAB share price.
INDSWFTLAB Quarterly Results — Revenue, Profit & EPS Highlights
Ind Swift Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with INDSWFTLAB DCF valuation to assess whether the stock is under or overvalued.
- Revenue of ₹171 Cr in Sept 2025 (-52.4% vs Mar 2025, +584.0% vs Sept 2024)
- Net Profit of ₹8 Cr in Sept 2025 (-96.4% vs Mar 2025)
- EBITDA of ₹19 Cr in Sept 2025 (-91.0% vs Mar 2025)
- Operating Margin of 1.0% in Sept 2025 (+8.0pp vs Mar 2025)
- Earnings Per Share of ₹1.00 in Sept 2025 (-97.0% vs Mar 2025)
Ind Swift Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDSWFTLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 171 | 359 | 167 | 178 | 25 | -52.4% | 584.0% |
| Net Profit (₹ Cr) | 8 | 222 | 9 | 10 | 0 | - | - |
| EBITDA (₹ Cr) | 19 | 211 | 18 | 26 | 1 | - | - |
| EPS (₹) | 1.00 | 32.96 | 1.28 | 1.17 | 0.07 | - | - |
| Operating Margin (%) | 1.0% | -7.0% | 2.0% | -1.0% | -99.0% | - | - |
INDSWFTLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Ind Swift Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore INDSWFTLAB price trends to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDSWFTLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Ind Swift Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores